TORONTO--(BUSINESS WIRE)--Today, Juno Pharmaceuticals Canada (“Juno”), a leader in the commercialization of specialty pharmaceuticals, announced the acquisition of Omega Laboratories (“Omega”), one of ...

Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") proudly announced the recipients of its second edition Health Equity ...

Fennec Pharmaceuticals ( ($TSE:FRX) ) just unveiled an update. Fennec Pharmaceuticals announced the successful closing of a non-brokered private ...

Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Canada Pharmaceutical Market Report by ATC / Therapeutic Class, Drug Type, Distribution Channel, Region, and Company Analysis, 2025-2033" report has been ...

ARS Pharmaceuticals, Inc. has announced the filing for approval of neffy® (epinephrine nasal spray) 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy®. This follows neffy's ...

--DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare, neurodevelopmental disorder SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ...

Health Canada is reshaping how medicines move through the regulatory system, pitching its agile licensing framework as a way ...

ADALAT® XL® (nifedipine extended-release tablets) first received market authorization in Canada in 1995 and is indicated for the management of chronic stable angina and the management of mild to ...

Canada has a one year grace period for public disclosures made by the applicant. Specific to pharma, Canada shares with the United States a generic drug regulatory regime which links patents listed on ...

Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. “Paul’s ...

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug ...